CELG-R

Bristol Myers - Celgene Cvr

+$12.8K

Net Activity

Institutions Holding

17

Popularity Rank

#8590

Avg Weight

0.00%

Total Value

$37.9K

Ownership Trend

17 institutions currently hold CELG-R, with 2 net buyers and 5 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Majority Decreased

Based on recent trading activity

Net Selling Institutions

5

Net Buying Institutions

2

Key Holders

View all 17 holding institutions

Quarterly Activity

Recent Activity

+$2.4K

Total Buy Value

$6.7K

Total Sell Value

New buy1
Trim3
Add1
Sold out2

2

Net Buyers

5

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding BRISTOL MYERS - CELGENE CVR (CELG-R)?
Major stakeholders currently include Transcend Capital Advisors, LLC ($12.7K), DAVENPORT & Co LLC ($9.7K), Bank Of America CORP /de/ ($5.8K). Based on the latest 13F filings, there are a total of 17 tracked investment funds and institutions maintaining positions in CELG-R.
What is the overall institutional sentiment toward CELG-R recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $12.8K, driven by 2 managers accumulating shares while 5 reduced their exposure.
Which institutions have been selling or reducing their CELG-R positions?
In the latest period, 3 funds trimmed their holdings, and 2 managers completely exited their positions. The aggregate reported sell value was $6.7K.
Are there any notable investors adding CELG-R to their portfolios?
Yes, buying activity remains notable. 1 institutions opened new positions in {ticker}, and 1 existing holders added to their shares. The total reported buy value for the quarter amounted to $2.4K.

Related Stocks